SRGN and plasma cell myeloma: Serglycin is also expressed by cancer cells, e. g. in acute myeloid leukemia and myeloma as well as by nasopharyngeal carcinoma cells and breast cancer cells, where a correlation between the level of serglycin proteoglycan expression and a more aggressive tumour cell phenotype has been found[13–17].